Posted by Michael Wonder on 24 Dec 2024
Blarcamesine receives EMA filing acceptance for treatment of Alzheimer’s disease
23 December 2024 - Submission based on favourable ANAVEX 2-73-AD-004 trial results in patients with early Alzheimer’s disease.
Anavex Life Sciences today announced that the EMA has accepted for review the marketing authorisation application for blarcamesine (ANAVEX 2-73), an investigational drug for the treatment of Alzheimer’s disease.
